Open Access

Selectively high efficacy of eribulin against high‑grade invasive recurrent and/or metastatic squamous cell carcinoma of the head and neck

  • Authors:
    • Yutaka Kobayashi
    • Hiroko Kitahara
    • Mariko Hirai
    • Akira Tanaka
    • Rei Jokaji
    • Kazuhiko Kobayashi
    • George Bou‑Gharios
    • Hiroyuki Nakamura
    • Shuichi Kawashiri
  • View Affiliations

  • Published online on: March 19, 2019     https://doi.org/10.3892/ol.2019.10165
  • Pages: 5064-5072
  • Copyright: © Kobayashi et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) have a poor prognosis. Over the past decade, a major development in the first‑line treatment of R/M SCCHN was the introduction of cetuximab in combination with platinum plus 5‑fluorouracil chemotherapy. Currently, a promising novel treatment option in R/M SCCHN has emerged, termed immune checkpoint inhibitors. However, only a few patients presenting with R/M SCCHN have exhibited meaningful tumor regression with these agents. Therefore, novel agents are required to order improve the overall survival of patients with R/M SCCHN. Recently, we demonstrated that R/M SCCHN cells are highly sensitive to eribulin. In the present study, the effects of eribulin, paclitaxel and vinblastine were investigated in R/M SCCHN (OLC‑01 and OSC‑19) and locally advanced SCCHN (OSC‑20) cells. Tumour‑inhibitory activities of eribulin against R/M SCCHN were evaluated in orthotopic xenograft models. The data revealed that eribulin has sub‑nM growth inhibitory activities in vitro against OLC‑01 cells, and that it is more potent than paclitaxel and vinblastine. The reduced expression of Tubulin Beta 3 Class III (TUBB3) following treatment was correlated with a high sensitivity to eribulin. Histological analysis of OLC‑01 cells in NOD‑SCID mice demonstrated that they had a higher invasiveness in the tissue around the alveolar cancer when compared with the histology of OSC‑19 cells, which has been reported in our previous study. Treatment with eribulin revealed marked inhibitory activities in vivo at 0.125 mg/kg against OLC‑01 cells orthotopic xenografts. In conclusion, the results highlight the existence of invasive‑type heterogeneity in R/M SCCHN with respect to eribulin sensitivity. Eribulin is already an approved clinical agent; therefore, the continued investigation of its preclinical antitumor attributes may contribute significantly to the future process of identifying novel uses of eribulin against R/M SCCHN.
View Figures
View References

Related Articles

Journal Cover

June 2019
Volume 17 Issue 6

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Kobayashi, Y., Kitahara, H., Hirai, M., Tanaka, A., Jokaji, R., Kobayashi, K. ... Kawashiri, S. (2019). Selectively high efficacy of eribulin against high‑grade invasive recurrent and/or metastatic squamous cell carcinoma of the head and neck. Oncology Letters, 17, 5064-5072. https://doi.org/10.3892/ol.2019.10165
MLA
Kobayashi, Y., Kitahara, H., Hirai, M., Tanaka, A., Jokaji, R., Kobayashi, K., Bou‑Gharios, G., Nakamura, H., Kawashiri, S."Selectively high efficacy of eribulin against high‑grade invasive recurrent and/or metastatic squamous cell carcinoma of the head and neck". Oncology Letters 17.6 (2019): 5064-5072.
Chicago
Kobayashi, Y., Kitahara, H., Hirai, M., Tanaka, A., Jokaji, R., Kobayashi, K., Bou‑Gharios, G., Nakamura, H., Kawashiri, S."Selectively high efficacy of eribulin against high‑grade invasive recurrent and/or metastatic squamous cell carcinoma of the head and neck". Oncology Letters 17, no. 6 (2019): 5064-5072. https://doi.org/10.3892/ol.2019.10165